Risk factors for the development of neuroleptic induced akathisia

Author： Miller C.H.   Hummer M.   Oberbauer H.   Kurzthaler I.   DeCol C.   Fleischhacker W.W.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.7, Iss.1, 1997-02, pp. : 51-55

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ritanserin in neuroleptic induced akathisia: a double blind comparison with placebo

By De Col C.   Miller C.H.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 349-349

Elsevier

Access to resources Recommend Favorite

A beta-adrenoceptor antagonist, carteolol, in the treatment of neuroleptic-induced akathisia

By Aoba A.   Murasaki M.   Kamijima K.   Yagi G.   Komemushi S.   Miura S.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 391-391

Elsevier

Access to resources Recommend Favorite

Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia

By Poyurovsky M.   Nave R.   Epstein R.   Tzischinsky O.   Schneidman M.   Barnes T.R.E.   Weizman A.   Lavie P.  

European Neuropsychopharmacology, Vol. 10, Iss. 3, 2000-05 ,pp. : 171-176

Elsevier

Access to resources Recommend Favorite

Managing Antipsychotic-Induced Acute and Chronic Akathisia

By Miller C.H.   Fleischhacker W.W.  

Drug Safety, Vol. 22, Iss. 1, 2000-01 ,pp. : 73-81

Adis International

Access to resources Recommend Favorite

Risperidone: Antipsychotic-induced akathisia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1427, 2012-01 ,pp. : 41-42

Adis International

Access to resources Recommend Favorite